GL1X · GenesisL1 explorer

Research workbench

CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor

Analyse CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
1H01
Type
protein
Length
287 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Cyclin-dependent kinase 2
EC
2.7.11.22
UniProt
P24941
Ligands
FAL, FBL
Pockets
1 · best druggability 0.68

Structure

x-ray diffraction · 1 distinct chain · 36% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACyclin-dependent kinase 2 (EC 2.7.11.22)protein28736% helix, 17% strandP24941

Ligands and binding sites

  • FAL · (2R)-1-[4-({4-[(2,5-dichlorophenyl)amino]pyrimidin-2-yl}amino)phenoxy]-3-(dimethylamino)propan-2-ol · ligand · chains A
  • FBL · (2S)-1-[4-({4-[(2,5-dichlorophenyl)amino]pyrimidin-2-yl}amino)phenoxy]-3-(dimethylamino)propan-2-ol · ligand · chains A
  • GOL · Glycerol · additive · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12700.680.8431GOL, FAL, FBL

Modifications

Observed in the structure: 1 modified (carboxylation).

Compared structures

  • 1H01 · CDK2 in complex with a disubstituted 2, 4-bis anilino pyrimidine CDK4 inhibitor · the same entry in another collection · chain A against A, TM-score 1.00
  • P24941 · AlphaFold monomer V2.0 prediction for cyclin-dependent kinase 2 (P24941) · a predicted model of the same protein · chain A against A, TM-score 0.94

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.